ADD1

ADD1 encodes a dual-function protein that operates both as a sequence-specific transcription factor controlling lipogenic gene programs and, in distinct cellular contexts, as a cytoskeletal adducin governing neural development and synaptic plasticity (PMID:8336713, PMID:22307086, PMID:34906466). As a basic helix-loop-helix leucine zipper factor, ADD1/SREBP1 binds DNA through an atypical tyrosine in its basic region that confers dual recognition of canonical E-boxes and the non-E-box sterol regulatory element SRE-1 (PMID:7739539), enabling direct transcriptional activation of lipogenic and metabolic targets including fatty acid synthase, ACC1, SCD1, 6-phosphogluconate dehydrogenase, and PGC1α (PMID:8336713, PMID:15466874, PMID:15896329, PMID:19962449). It further drives adipogenic signaling by stimulating production of secreted endogenous lipid ligands that directly activate PPARγ (PMID:9539737). This transcriptional output is negatively regulated by GSK3β-mediated phosphorylation (PMID:15466874) and by physical interactions with the dominant-negative HLH proteins Id2/Id3 and with Twist2, which block ADD1 DNA binding (PMID:10585876, PMID:14654692, PMID:37761873). In neural contexts, ADD1 functions through actin-capping activity to consolidate synaptic plasticity and stabilize AMPA-type glutamate receptors (PMID:22307086), and to control the morphology and proliferation of neocortical progenitors [PMID:bio_10.1101_2024.11.08.622634]. Human loss-of-function ADD1 variants cause intellectual disability, corpus callosum dysgenesis, and ventriculomegaly, phenotypes recapitulated in Add1 knockout mice, with patient variants impairing ADD1 protein expression and dimerization with ADD2 (PMID:34906466). ADD1 additionally translocates to the nucleus downstream of CTSB S-nitrosylation to recruit MATR3 and ADAR1, promoting A-to-I editing and stabilization of CTSB mRNA (PMID:37156877).

1. 1993 High

   Established ADD1 as a novel bHLH-leucine zipper transcription factor that binds DNA and activates transcription in adipocytes, defining its identity as a sequence-specific regulator of adipogenic gene expression.

   Evidence Oligonucleotide cDNA library screening, CAT reporter assays, and DNA-binding specificity assays in adipocytes

   PMID:8336713

   Open questions at the time

   • Did not define the full target gene set
   • No structural basis for DNA recognition
2. 1995 High

   Resolved how ADD1 achieves dual DNA-binding specificity, showing a single atypical tyrosine in the basic region permits recognition of both E-box and SRE-1 elements, distinguishing it from canonical E-box-only bHLH factors.

   Evidence Site-directed mutagenesis of the bHLH basic region with bidirectional swap mutations and reporter assays in fibroblasts

   PMID:7739539

   Open questions at the time

   • Did not establish which target genes use E-box versus SRE-1 in vivo
3. 1998 High

   Showed ADD1 acts upstream of PPARγ by inducing secreted endogenous lipid ligands, linking ADD1 transcriptional activity to a paracrine adipogenic signaling axis.

   Evidence Gal4-PPARγ chimeric reporter assays, conditioned medium transfer, and radioligand displacement binding

   PMID:9539737

   Open questions at the time

   • Chemical identity of the endogenous ligand(s) not determined
   • Biosynthetic enzymes downstream of ADD1 unidentified
4. 1999 Medium

   Identified Id2/Id3 as dominant-negative HLH antagonists that sequester ADD1 away from DNA, providing a mechanism for negative control of lipogenic activation.

   Evidence Reciprocal co-IP of in vitro-translated proteins, gel shift, and reporter assays in adipocytes and NIH-3T3 cells

   PMID:10585876

   Open questions at the time

   • Single lab
   • Physiological conditions controlling Id2/Id3 levels not addressed
5. 2003 Medium

   Established Twist2 as an N-terminal-binding repressor of ADD1 that reduces DNA binding with a chromatin-modifying component, expanding the repertoire of ADD1 transcriptional repressors.

   Evidence Yeast two-hybrid screen, co-IP, DNA-binding and reporter assays, and HDAC inhibitor treatment

   PMID:14654692

   Open questions at the time

   • Single lab
   • Identity of recruited HDAC not defined
6. 2004 High

   Demonstrated GSK3β directly phosphorylates ADD1 to suppress its transcriptional output, placing ADD1 under kinase-dependent post-translational control of lipogenesis.

   Evidence In vitro kinase and in vivo phosphorylation assays, GSK3 inhibition, GSK3β overexpression, and target gene readouts

   PMID:15466874

   Open questions at the time

   • Phosphorylation sites not mapped
   • Upstream signals controlling GSK3β toward ADD1 unclear
7. 2004 Medium

   Showed via reciprocal congenic rat strains that Add1 allelic variation causally contributes to blood pressure regulation, distinguishing it functionally from Add2 and Add3.

   Evidence Reciprocal congenic strain construction and systolic blood pressure measurement with chromosomal substitution mapping

   PMID:15474463

   Open questions at the time

   • Molecular mechanism linking Add1 allele to blood pressure not defined
   • Relationship to transcription factor vs cytoskeletal function unresolved
8. 2005 Medium

   Connected ADD1 to insulin/PI3-kinase signaling by demonstrating direct E-box-dependent activation of the 6PGDH gene, extending its targets to the pentose phosphate pathway.

   Evidence DNase I footprinting, promoter point mutation, reporter assays, and PI3-kinase inhibitor treatment

   PMID:15896329

   Open questions at the time

   • Single lab
   • Direct phosphorylation events linking PI3K to ADD1 not shown
9. 2009 Medium

   Showed β-adrenergic signaling recruits ADD1 to a conserved E-box in the PGC1α promoter, linking ADD1 to thermogenic/mitochondrial transcriptional programs in brown-like adipocytes.

   Evidence Reporter assays, ChIP, and β-adrenergic stimulation in adipocyte models

   PMID:19962449

   Open questions at the time

   • Cell-type-restricted cofactors required for activation unidentified
   • Single lab
10. 2012 High

    Revealed a distinct cytoskeletal role for ADD1 in neurons, showing α-adducin actin-capping activity is required to consolidate synaptic plasticity and stabilize AMPA receptors during memory storage.

    Evidence C. elegans add-1 loss-of-function genetics, olfactory conditioning behavior, GLR-1 imaging and FRAP, and human ADD1 rescue

    PMID:22307086

    Open questions at the time

    • Mechanistic link between actin-capping and receptor retention not fully resolved
    • Mammalian synaptic validation limited
11. 2012 Medium

    Defined non-erythroid requirements for α-adducin in vivo, with Add1 knockout mice showing skeletal, esophageal, and peripheral nerve phenotypes.

    Evidence Add1 null mouse histology of spine and esophagus and peripheral nerve axon counts

    PMID:22926980

    Open questions at the time

    • No molecular mechanism identified
    • Tissue-specific contributions not dissected
12. 2021 High

    Established ADD1 as a human disease gene, with loss-of-function variants causing intellectual disability and brain malformations through impaired ADD1 expression and ADD2 dimerization.

    Evidence Exome and RNA sequencing, super-resolution imaging, immunoblotting, in vitro ADD1–ADD2 dimerization assays, and Add1 knockout mouse recapitulation

    PMID:34906466

    Open questions at the time

    • Cellular mechanism linking dimerization loss to corpus callosum dysgenesis incomplete
    • Splice-isoform-specific functions not fully defined
13. 2023 Medium

    Uncovered a nuclear RNA-regulatory function for ADD1, in which dephosphorylation-driven nuclear translocation recruits MATR3 and ADAR1 to promote A-to-I editing and stabilization of CTSB mRNA.

    Evidence S-nitrosylation assays, nuclear fractionation, co-IP of the ADD1–MATR3–ADAR1 complex, RNA editing and stability assays, and HuR binding assays

    PMID:37156877

    Open questions at the time

    • Single lab without independent replication
    • Generality beyond CTSB unknown
14. 2023 Medium

    Identified CHRDL1 as an ADD1 transcriptional target and showed TWIST2, but not TWIST1, competes at the shared E-box, refining the specificity of Twist-family repression of ADD1.

    Evidence EMSA, luciferase reporter assays, and EMSA competition with TWIST2/TWIST1 and disease-mutant variants

    PMID:37761873

    Open questions at the time

    • Single lab
    • In vivo relevance of CHRDL1 regulation not established
15. 2024 Medium

    Linked ADD1 to neocortical expansion by showing adducins regulate basal progenitor morphology and proliferative capacity across species.

    Evidence Mouse and ferret in vivo neocortex electroporation, human cortical organoid ADD1 knockout, and imaging/cell counting (preprint)

    PMID:bio_10.1101_2024.11.08.622634

    Open questions at the time

    • Preprint, not yet peer-reviewed
    • Molecular mechanism connecting adducin to progenitor proliferation unresolved

• How the same protein partitions between its transcription-factor and cytoskeletal/RNA-regulatory roles, and what controls isoform- and tissue-specific deployment, remains unresolved.
• No unified model reconciling metabolic transcription factor and neuronal adducin functions
• Determinants of subcellular partitioning (nucleus vs cytoskeleton) undefined
• Isoform-specific functional assignment incomplete